Treace Medical Reports Q3 2026 Revenue Decline Amid Improved Profitability Metrics
Treace Medical (TMCI) reported third-quarter revenue of $48.3 million, a 4% decrease year-over-year attributed to a shift in product mix toward lower-priced items and reduced bunion procedure kit volumes. Despite the top-line contraction, the company achieved a positive inflection in Adjusted EBITDA, reporting $300,000 compared to a loss of $2.6 million in the prior year period. The company demonstrated significant progress in cost management, reducing total operating expenses by 10% and narrowing its full-year Adjusted EBITDA loss guidance. Management highlighted increased surgeon adoption rates for new bunion systems and an expanded product portfolio that now addresses over 80% of a reconstructive surgeon's typical volume, up from 30% last year.
Tickers: $TMCI
Topics: EBITDA inflection gross margin expansion guidance update net loss improvement revenue decrease